Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

References

• Davies MJ D’Alessio DA Fradkin J Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2018 61 12 2461 2498 30288571
   PubMed Web of Science ®Google Scholar
• Garber AJ Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability Diabetes Care 2011 34 Supplement 2 S279 S284 21525469
   PubMed Web of Science ®Google Scholar
• Victoza® package insert Plainsboro Township, NJ Novo Nordisk 2018
   Google Scholar
• Saxenda® package insert Plainsboro, NJ Novo Nordisk 2014
   Google Scholar
• Prasad-Reddy L Isaacs D A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond Drugs Context 2015 4 212283 26213556
   PubMedGoogle Scholar
• Jacobsen LV Flint A Olsen AK Ingwersen SH Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics Clin Pharmacokinet 2016 55 6 657 672 26597252
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brändle M Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 3 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with met-formin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial The Lancet 2009 373 9662 473 481
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 2009 32 7 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 2009 52 10 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) The Lancet 2009 374 9683 39 47
   PubMed Web of Science ®Google Scholar
• Davies MJ Bergenstal R Bode B Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the scale diabetes randomized clinical trial JAMA 2015 314 7 687 699 26284720
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X Astrup A Fujioka K A randomized, controlled trial of 3.0 mg of liraglutide in weight management N Engl J Med 2015 373 1 11 22 26132939
   PubMed Web of Science ®Google Scholar
• Jacobsen LV Hindsberger C Robson R Zdravkovic M Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide Br J Clin Pharmacol 2009 68 6 898 905 20002084
   PubMed Web of Science ®Google Scholar
• Flint A Nazzal K Jagielski P Hindsberger C Zdravkovic M Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide Br J Clin Pharmacol 2010 70 6 807 814 21175436
   PubMed Web of Science ®Google Scholar
• Hiramatsu T Ozeki A Asai K Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis Ther Apher Dial 2015 19 6 598 605 26556397
   PubMed Web of Science ®Google Scholar
• Vergès B Duvillard L Pais de Barros JP Liraglutide reduces postprandial hyperlipidemia by increasing apoB48 (apolipoprotein B48) catabolism and by reducing apoB48 production in patients with type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 2018 38 9 2198 2206 30026275
   PubMed Web of Science ®Google Scholar
• Hermansen K Bækdal TA Düring M Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial Diabetes Obes Metab 2013 15 11 1040 1048 23683069
   PubMed Web of Science ®Google Scholar
• Kumarathurai P Anholm C Larsen BS Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study Diabetes Care 2017 40 1 117 124 27797930
   PubMed Web of Science ®Google Scholar
• Faber R Zander M Pena A Michelsen MM Mygind ND Prescott E Effect of the glucagon-like peptide-1 analogue liraglutide on coronary micro-vascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study Cardiovasc Diabetol 2015 14 1 1 11 25582325
   PubMed Web of Science ®Google Scholar
• Kajiwara M Tanaka A Kawasaki T Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: a non-randomized interventional pilot trial J Cardiol 2017 69 3 511 517 27894787
   PubMed Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
   PubMed Web of Science ®Google Scholar
• Marso SP Nauck MA Monk Fries T Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the leader trial) Am J Cardiol 2018 121 12 1467 1470 29627109
   PubMed Web of Science ®Google Scholar
• Liu Y Jiang X Chen X Liraglutide and metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease Lipids Health Dis 2017 16 1 227 29197387
   PubMed Web of Science ®Google Scholar
• Sun F Yu K Wu S Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis Diabetes Res Clin Pract 2012 98 3 386 395 23020934
   PubMed Web of Science ®Google Scholar
• Mannucci E Monami M Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials Adv Ther 2017 34 1 1 40 27844335
   PubMed Web of Science ®Google Scholar
• Byetta® package insert Wilmington, ED AstraZeneca 2015
   Google Scholar
• Bydureon® [package insert] Wilmington, ED AstraZeneca 2017
   Google Scholar
• Trulicity® [package insert] Indianapolis, IN Eli Lilly 2018
   Google Scholar
• Adlyxin™ [package insert] Bridgewater, NJ Sanofi-Aventis 2016
   Google Scholar
• Ozempic® [package insert] Plainsboro, NJ Novo Nordisk 2017
   Google Scholar